Most reports on the combination of RT and ICIs refer to patients with malignant melanoma treated with ipilimumab targeting the CTLA4 checkpoint, since it was approved for the treatment of metastatic melanoma in 2011 (Postow et al., 2012; Theurich et al., 2016). Here, CTLA4 is linked to melanoma.